Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of CD101 (Rezafungin) in Healthy Subjects
NCT02516904Phase 1Completed
- Sponsor
- Cidara Therapeutics
- Start
- Jul 2015
- Primary completion
- Oct 2015
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in invasive candidiasis and candidemia comparing CD101 IV with Placebo (2 arms). Primary endpoint: Number of subjects with clinically significant adverse events (AEs) up to 3 weeks. Started Jul 2015; status: completed.
02
Drugs
rezafungin
03
Conditions
invasive candidiasiscandidemia
Beyond the preview
Go deeper on NCT02516904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516904.